Atropine and paralytic ileus

NEIL BEATSON
M.B., B.S.

Department of Surgery, Royal South Hants Hospital, Southampton

Summary
A patient who developed paralytic ileus while on atropine therapy is described, and this complication of atropine-like drugs is reviewed.

Introduction
Drugs are an important cause of paralytic ileus and failure to recognize this may lead to unnecessary laparotomy. Atropine is an anti-muscarinic alkaloid and its action in decreasing the motility of intestine is well known.

However, paralytic ileus as a complication of atropine therapy has not to my knowledge previously been reported.

Case report
A 77-year-old man was admitted from a nearby geriatric unit with a 24-hr history of vomiting and epigastric pain. He had previously been well, although limited by Parkinson’s disease which was controlled with Sinemet 275 (levodopa and carbidopa) one tablet daily.

For the previous 4 months, distressing excessive salivation had been successfully treated with 0.6 mg atropine sulphate daily given orally. He was also taking bendrofluazide 5 mg daily, slow K 2 tablets daily and indomethacin 25 mg twice daily.

He had not demonstrated any signs of excessive anticholinergic activity before his present illness and occasionally had needed Lomotil (atropine and diphenoxylate) for bouts of loose bowel motions which were not thought to be significant.

Examination revealed a withdrawn, dehydrated patient with a slightly distended abdomen and absent bowel sounds. He showed tenderness without guarding in the epigastrium. There were no other demonstrable signs of atropine poisoning; his heart rate was regular 56 per min. The pupils were not dilated, the skin was of normal temperature and colour and his mental state, although depressed, was thought to be due to the combination of his Parkinson’s disease and dehydration.

Biochemical and haematological investigations were all unremarkable. Plain X-rays of the abdomen showed massive dilatation of stomach and small intestine (Fig. 1).

All drugs were stopped and conservative treatment was commenced with nasogastric aspiration and intravenous fluid replacement. By the fourth day after admission the patient was much improved, taking oral fluids, having a normal bowel action and much more alert.

Repeat plain abdominal X-rays showed the bowel to have been decompressed. The patient was recommenced on his previous medication minus the atropine.

Discussion
George (1980) has recently reviewed drugs causing intestinal obstruction and mentions that atropine-like compounds do not usually give rise to problems, except in overdose or when combined with an opiate. Indeed, standard textbooks of pharmacology suggest that the dosage of atropine necessary to suppress the motility of the gastrointestinal tract is greater than that necessary either to block salivary secretion or increase the heart rate.

However, earlier literature suggests that often the dosage and the length of therapy do not play a significant part in the development of the ileus for ganglion blocking drugs (Munster and Milton, 1961) or amitriptyline (Milner and Buckler, 1964). The case described here would appear to support this view.

Anti-cholinergic activity is a property of many drugs and most notably the tricyclic anti-depressants have been reported as causing paralytic ileus (Milner and Buckler, 1964; Milner and Hills, 1966).

Phenothiazines, specifically chlorpromazine, are also a recognized cause, thought to be due to their weak atropinic properties (Sriram et al., 1979). However, with this latter group of drugs it is thought that the development of the ileus is dose related, as it is most often seen in the mentally disturbed patient who may be on huge doses of chlorpromazine.
Haloperidol, another neuroleptic drug has also been incriminated (Maltbie et al., 1981). Phenothiazines may also act to cause ileus via their anti-histaminic properties. Histamine is thought to act directly or indirectly to stimulate gastrointestinal motility (George, 1980), although with one exception (Watson, Knutty and Colclough, 1977) the H₂ antagonists have not been incriminated. Parkinson's disease itself may cause constipation (Simpson, 1978), and thus patients receiving anticholinergic therapy for Parkinson's disease are more prone to ileus by the very nature of their disease (Daggett and Ibrahim, 1976).

Atropinic properties of drugs are therefore an important cause of paralytic ileus. This may be an idiosyncratic phenomenon as well as dose related, or it may occur when in combination with other drugs predisposing to bowel immobility, such as opiates. Some drugs, most notably the mono-amine oxidase inhibitors, prolong the detoxification of anti-cholinergic drugs and account should also be taken of this (Goodman and Gilman, 1980).

Postoperatively ileus may be prolonged due to concomitant anti-cholinergic therapy being taken by the patient on admission.

Treatment of established anti-cholinergic induced ileus is conservative, as in this case. Little has been published on the effect of the use of anti-cholinesterase drugs such as neostigmine in these patients, although Sriram et al. (1979) have had some success with these drugs and it would seem sound practice to institute such therapy.

Acknowledgments

I should like to thank Mr A. D. B. Chant for permission to report on his patient, Professor C. F. George for his encouragement and Mrs S. E. Gough and Miss L. G. Jennings for the typing of the manuscript.

References


Clinical reports


Atropine and paralytic ileus

Neil Beatson

*Postgrad Med J* 1982 58: 451-453
doi: 10.1136/pgmj.58.681.451

Updated information and services can be found at:
http://pmj.bmj.com/content/58/681/451

These include:

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/